Stockreport

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors [Financial Post (Toronto, Ontario, Canada)]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF Author of the article: You can save this article by registering for free here . Or sign-in if you have an account. (cabozantinib) versus placebo in advanced pancrea [Read more]